What do systematic reviews say?

Doxycycline 40 mg + azelaic acid gel vs doxycycline 40 mg + metronidazole gel

Doxycycline 40 mg + azelaic acid gel showed no clear difference in proportion of participants with adverse event compared with doxycycline 40 mg + metronidazole gel (high certainty).

• Interventions for rosacea 2015 · Cochrane Headline outcomes only
  RR 0.27 [0.06, 1.28]
  1 study · 207 participants
  High

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

The review found no eligible studies for this question.

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

It is very uncertain whether flutamide 250 mg once to twice daily changes proportion of participants who reported an adverse event compared with metformin 1275 mg to 1700 mg per day (very low certainty).

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  RR 2 [0.41, 9.71]
  1 study · 40 participants
  Very low

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 95 participants
  Very low

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 95 participants
  Moderate

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 95 participants
  Very low

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

• Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 55 participants
  Moderate

Fluticasone propionate spray vs Betamethasone sodium phosphate mouthwash

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  No statistical testing of the Oral Health Quality of Life index (OHQoL16) was reported in Hegarty 2002 (fluticasone mean score 0.7 versus betamethasone mean score -0.8).
  1 study · 22 participants
  GRADE not reported

Fluticasone propionate spray vs Betamethasone sodium phosphate mouthwash

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  In the Hegarty 2002 cross-over trial (n=22), no statistical testing of the pain score (VAS 0 to 100) was reported; it is not clear whether the difference is statistically significant (fluticasone mean score 19.8 versus…
  1 study · 22 participants
  GRADE not reported

Fluticasone propionate spray vs Betamethasone sodium phosphate mouthwash

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  No statistical testing of the mean surface area of lesions was reported in Hegarty 2002 (fluticasone mean score 547.2 mm2 versus betamethasone mean score 671.9 mm2).
  1 study · 22 participants
  GRADE not reported

Fluticasone propionate spray vs Betamethasone sodium phosphate mouthwash

• Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
  Table 3 (Side-effects). Hegarty 2002: nausea (4), swollen mouth (1), bad taste and smell (6), difficulty in spray application (7), dry mouth (2), sore throat (1), red painful tongue (1), and pseudomembranous…
  1 study · 44 participants
  GRADE not reported

Summary of findings table ‐ Oral classical immunosuppressants (prednisolone or cyclosporine) vs placebo

It is very uncertain whether summary of findings table ‐ Oral classical immunosuppressants… changes short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (very low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 4.68 [0.57, 38.27]
  2 studies · 79 participants
  Very low

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in short‐term hair regrowth ≥ 75% compared with placebo (low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 3.59 [0.19, 66.22]
  1 study · 60 participants
  Low

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

Summary of findings table ‐ Subcutaneous biologics (dupilumab) showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.54 [0.07, 36.11]
  1 study · 60 participants
  Low

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Subcutaneous biologics (dupilumab) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Summary of findings table ‐ Oral small molecule inhibitors… leads to higher short‐term hair regrowth ≥ 75% (between 12 and 26 weeks of compared with placebo (high certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 7.54 [3.9, 14.58]
  2 studies · 1200 participants
  High

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

Summary of findings table ‐ Oral small molecule inhibitors… showed no clear difference in incidence of serious adverse events compared with placebo (low certainty).

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  RR 1.47 [0.6, 3.6]
  3 studies · 1224 participants
  Low

Summary of findings table ‐ Oral small molecule inhibitors (apremilast or baricitinib) vs placebo

The review found no eligible studies for this question.

• Treatments for alopecia areata: a network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found